Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Novo Nordisk launched clinical trials of the medication as an obesity treatment, and, following positive results, a double-strength version just for weight management was released in the US in 2014 under the brand name Saxenda
Ongoing clinical studies and trials are evaluating its full potential and safety profile
If other programs interest you, visit omzo.com and review their Terms, eligibility criteria, and pricing directly
Results from an initial Phase III trial in December also did not meet expectations, which triggered a 19% decline in Novos share price
US$ 24.69
US$ 23.52
US$ 26.31
US$ 26.99
US$ 21.86
US$ 25.24
